View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 12, 2020

Japan expects to launch clinical trials of Covid-19 vaccine in July

Japan is expecting to launch clinical trials of Covid-19 vaccine in July, said the country’s Prime Minister Shinzo Abe at a budget committee session.

Japan is expecting to launch clinical trials of Covid-19 vaccine in July, said the country’s Prime Minister Shinzo Abe at a budget committee session.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Multiple institutions in the country are working on a potential vaccine, including the National Institute of Infectious Diseases, University of Tokyo and Osaka University.

Abe added that Japan would join several other countries trying to develop a Covid-19 vaccine. The Prime Minister called for more vaccination programmes as early as possible along with the pooling of global resources and know-how, reported Xinhua.

In addition, Abe said that the government intends to approve Fujifilm’s anti-flu drug Avigan by the end of this month for the treatment of patients suffering from Covid-19 infection.

Japan is said to be planning to increase its Avigan stockpile by three times to treat two million people. Foreign Minister Toshimitsu Motegi noted that the drug will be made available at zero cost to more than 40 countries for clinical trials.

Avigan (favipiravir) selectively blocks RNA polymerase involved in influenza viral replication. The mechanism is expected to have an antiviral activity against SARS-CoV-2, the novel coronavirus that causes Covid-19.

The drug is manufactured and distributed upon request by the government of Japan. It was never distributed in the market and is not available at hospitals and pharmacies in Japan or internationally.

Last month, Fujifilm Toyama Chemical commenced a Phase III clinical trial of Avigan  for the treatment of Covid-19 patients in Japan. The study will assess the drug’s safety and efficacy.

Fujifilm also launched a Phase II trial of Avigan to treat Covid-19 patients in the US. This study is designed for around 50 coronavirus patients will be enrolled at Brigham and Women’s Hospital, Massachusetts General Hospital and the University of Massachusetts Medical School.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena